Details for Patent: 7,563,801

Which drugs does patent 7,563,801 protect, and when does it expire?

Patent 7,563,801 protects VARUBI and is included in one NDA.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 7,563,801

Title:	Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same
Abstract:	Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro [4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Inventor(s):	Qiu; Zhihui (Bridgewater, NJ), Reyderman; Larisa (Watchung, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/732,663
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Process;

Drugs Protected by US Patent 7,563,801

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes			Y

International Family Members for US Patent 7,563,801

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060303
Australia	2007233389
Brazil	PI0710577
Canada	2648640
Canada	2861281
Chile	2007000945